Kuvan (Sapropterin Dihydrochloride)

Sapropterin dihydrochloride provides an exogenous source of tetrahydrobiopterin, the natural cofactor for phenylalanine hydroxylase. By increasing the availability of this cofactor, the drug enhances the enzyme’s ability to convert phenylalanine into tyrosine, thereby reducing phenylalanine accumulation in the bloodstream.

The dosage of Kuvan is individualized and determined by the prescribing healthcare professional based on the patient’s age, weight, metabolic response, and blood phenylalanine levels. Patients should follow the prescriber’s instructions and not adjust the dose without medical guidance.

Kuvan is classified as Pregnancy Category B, indicating that animal studies have not shown risk but there are limited human data. It may be used during pregnancy only if the potential benefit justifies any potential risk. Caution is advised while breastfeeding, and infants should be monitored for any adverse effects.

To request Kuvan, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Kuvan is a synthetic BH4 analogue that works by enhancing the activity of phenylalanine hydroxylase, unlike dietary restriction alone or enzyme substitution therapies. It is particularly useful for patients who are BH4‑responsive, offering the potential to relax dietary limits, whereas other treatments may not provide this metabolic advantage.

Kuvan tablets should be stored at room temperature, below 25 °C. Keep them in the original packaging, protect them from moisture and excessive heat, and store them out of reach of children to maintain product stability.

Kuvan is taken orally as a tablet. The tablet should be swallowed whole with water, following the dosing schedule prescribed by the healthcare provider. It is not intended for crushing, chewing, or splitting unless specifically instructed by a medical professional.

Serious risks, although rare, include anaphylactic reactions, severe allergic dermatitis, eosinophilia, significant liver enzyme elevations, and seizures. Patients should seek immediate medical attention if they experience symptoms such as difficulty breathing, rash spreading rapidly, jaundice, or unexplained neurological changes.

Kuvan should not be used by individuals who are not BH4‑responsive, have a known hypersensitivity to sapropterin dihydrochloride or any tablet excipients, or who are taking conflicting BH4 analogues without medical supervision. Patients with severe liver disease or uncontrolled renal impairment should also avoid use unless closely monitored.